Paradigms of megapolis nephrology in a changing world: status, problems and prospects of development of the nephrological service of St. Petersburg

   The course of the COVID-19 pandemic has led to a critical increase in the burden on virtually all major branches of the health care system in our country and abroad.

   The aim of this article is to analyse the activities of the different parts of the city nephrol­ogy service in Saint-Petersburg and to consider promising ways to improve it.

   The nephrology service for the adult population in St. Petersburg includes: outpatient service; inpatient service - 183 beds in 24-hour inpatient departments of the city; dialysis service - 10 dialysis units in municipal medical organizations, 5 in federal institutions, and 8 centers/departments operating in the framework of private-public partnership. The number of patients on dialysis programme decreased by 10.5 % to 1,839 in 2021. These changes are likely due to an increase in mortality among these patients in 2020 and 2021 which is a consequence not only of COVID-19 but also of the adverse impact of the pandemic on the health system. The proportion of patients treated as outpatients in private dialysis centres increased during the three-year period. The incidence of arteriovenous fistula formation in primary vascular access decreased from 33.2 % to 14.2 % in 2020 compared with 2019. At the same time, the use of temporary central venous catheters as primary vascular access for renal replacement therapy has increased significantly from 43.0 % to 61.9 %. The development of the nephrology service is largely determined by its funding. To compensate the costs of medical in­ stitutions in the city for conducting renal replacement therapy it is necessary to increase the tariffs of compulsory health insurance (CHI) by at least 50 %. In the medical organizations of Saint-Petersburg municipal and federal subordination the share of "artificial kidney" devices that have used up their resource is 32.2 %, and in a number of medical institutions it exceeds 50 %.

1. Gemelli Against COVID-19 Post-Acute Care Study Group. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res 2020; 32 (8): 1613–1620. doi: 10.1007/s40520-020-01616-x

2. Sohrabi C., Alsafi Z., O'Neill N. et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71–76. doi: 10.1016/j.ijsu.2020.02.034

3. Dobronravov V. A., Vatazin A. V., Smirnov A. V., Batiushin M. M., Bobkova I. N., Zulkarnaev А. B., Antonova E. V., Butrimova S. S., Bush M. V., Zhukova L. G., Politov D. V., Stepanov V. N., Tkachenko E. V., Shumilina A. A. Renal service during the COVID-19 pandemic (Association of nephrologists position statement). Nephrology (Saint-Petersburg) 2021; 25 (1): 9–17. (In Russ.) doi: 10.36485/1561-6274-2021-25-1-9-17

4. Yaroustovsky M. B., Shukevich D. L., Ushakova N. D., Sokolov A. A., Rey S. I. Blood purification methods in complex treatment of patients with a new coronavirus infection. Russian Journal of Anaesthesiology and Reanimatology 2020; (5): 47–55. (In Russ.) doi: 10.17116/anaesthesiology202005147

5. Cheng Y., Luo R., Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97 (5): 829–838. doi: 10.1016/j.kint.2020.03.005

6. Nadim M. K., Forni L. G., Mehta R. L. et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol 2020; 16 (12): 747–764. doi: 10.1038/s41581-020-00356-5

7. Hilbrands L. B., Duivenvoorden R., Vart P. et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020; 35 (11): 1973–1983. doi: 10.1093/ndt/gfaa261

8. Gansevoort R. T., Hilbrands L. B. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol 2020; 16 (12): 705–706. doi: 10.1038/s41581-020-00349-4

9. Ateya A. M. CKD patients: A high-risk category for severe COVID-19. J Med Virol 2021; 93 (7): 4086–4087. doi: 10.1002/jmv.26929

10. Xu C., Zhang T., Zhu N., Han M. Characteristics of COVID-19 patients with preexisting CKD history. Int Urol Nephrol 2021; 53 (12): 2567–2575. doi: 10.1007/s11255-021-02819-5

11. Yang D., Xiao Y., Chen J. et al. COVID-19 and chronic renal disease: clinical characteristics and prognosis. QJM 2020; 113 (11): 799–805. doi: 10.1093/qjmed/hcaa258

12. Alberici F., Delbarba E., Manenti C. et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int 2020; 98 (1): 20–26. doi: 10.1016/j.kint.2020.04.030

13. Kular D., Chis Ster I., Sarnowski A. et al. The Characteristics, Dynamics, and the Risk of Death in COVID-19 Positive Dialysis Patients in London, UK. Kidney360 2020; 1 (11): 1226–1243. doi: 10.34067/KID.0004502020

14. Yavuz D., Karagöz Özen D. S., Demirağ M. D. COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis. Int Urol Nephrol 2022: 1–6. doi: 10.1007/s11255-022-03193-6